Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this project is to study the survival of patients until Haematopoietic Stem
Cell Transplantation following the use of Ruxolitinib as first-line treatment associated to
corticosteroids in primary HLH.